No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 36 of the 40 quarters in the window, leaving 4 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 89.8x · 10Y median 89.3x · 54th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:32:53.020Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for MediciNova, Inc. (MNOV) stock was $1.68 as of Oct 6, 2026, 10:30 AM EDT, down 4.27% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +37.3% · 3-year avg -4.0%/yr · 5-year avg -13.6%/yr
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States.
Biotechnology · La Jolla, CA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.06
Revenue Est.
$50000.00
Last Quarter Results
EPS
$-0.05
vs Estimate
$-0.07
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MNOV | $82.69M | $1.68 | -4.27% | +37.29% | -13.62% | -13.11% | N/A |
| 2ACRV | $82.61M | $1.93 | -2.53% | +3.65% | N/A | N/A | vs MNOV |
| 3CTOR | $81.83M | $0.88 | +0.76% | -53.61% | N/A | N/A | vs MNOV |
| 4LNSR | $81.43M | $6.63 | -0.60% | -45.13% | -3.18% | N/A | vs MNOV |
| 5HUMA | $84.13M | $0.50 | +0.16% | -76.03% | -45.73% | N/A | vs MNOV |
| 6ATRA | $84.15M | $9.34 | -0.64% | -34.63% | -53.60% | -32.27% | vs MNOV |
forward FY estimate
N/A
$459000.00
vs Estimate
$75000.00
Consensus Rating
Based on 4 analysts
Average Price Target
$8.25
+391.1% upside
Low
$6.00
Current
$1.68
High
$11.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.06 | $-0.06 | $-0.06 | 2 |
| Quarter ending Dec 2026 | $-0.10 | $-0.08 | $-0.06 | 2 |
| Quarter ending Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.27 | $-0.26 | $-0.23 | 3 |
| FY 2027 | $-0.50 | $-0.45 | $-0.39 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $50000.00 | $50000.00 | $50000.00 | 2 |
| Quarter ending Dec 2026 | $33333.00 | $33333.00 | $33333.00 | 2 |
| Quarter ending Mar 2027 | $272589.00 | $272589.00 | $272589.00 | 1 |
| Quarter ending Jun 2027 | $229219.00 | $229219.00 | $229219.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $452678.00 | $536250.00 | $626785.00 | 2 |
| FY 2027 | $295303.00 | $500000.00 | $706656.00 | 2 |
